| Status | Study |
| Recruiting |
Study Name: Virus Specific Immune Lymphocytes (Virus-CTL) in the Treatment of Opportunistic Viral Diseases Post Transplantation Condition: Virus Infection EBV Infection Cytomegalovirus Infections Date: 2017-05-16 Interventions: Biological: CMV/EBV/ADV/BKV specific CTLs Patients will receive approximately 1x10^5~4x10^6 CTLs/kg as a |
| Recruiting |
Study Name: A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 Condition: Adenoviral Infection Date: 2017-05-15 Interventions: Biological: PXVX0047 Vaccine P |
| Recruiting |
Study Name: Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma Condition: Glioma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Date: 2017-02-20 Interventions: Biological: Neural stem cells loaded with an oncolytic adenovirus The primary objectives are to evaluate |
| Recruiting |
Study Name: Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 Condition: Colorectal Cancer Date: 2017-02-10 Interventions: Drug: Avelumab Intravenous inf |
| Recruiting |
Study Name: Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer Condition: Non-small Cell Lung Cancer Stage I Date: 2017-01-19 Interventions: Biological: Ad5-yCD/mutTKSR39rep-ADP Adenovirus oncolytic adenovirus |
| Not yet recruiting |
Study Name: Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris Condition: Refractory Angina Pectoris Gene Transfer Coronary Artery D Date: 2017-01-03 Interventions: Drug: AdvVEGF-D AdvVEGF-D will |
| Recruiting |
Study Name: A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade Condition: Advanced or Unresectable Melanoma Progressing After PD1 Blockade Date: 2016-12-19 Interventions: Biological: ONCOS-102 Engineer |
| Completed |
Study Name: Specific Respiratory Infections as Triggers of Acute Medical Events Condition: Influenza, Human Respiratory Syncytial Virus Infections Pa Date: 2016-12-02 |
| Active, not recruiting |
Study Name: Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults Condition: Human Immunodeficiency Virus Date: 2016-09-01 Interventions: Biological: Ad26.Mos.HIV Recom |
| Recruiting |
Study Name: Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients Condition: Non-Small Cell Lung Cancer Date: 2016-08-15 Interventions: Biological: Ad-MAGEA3 Biological: MG1-MAGE |